Visit Trove at the National Library of Australia to read archived TGA publications
Latest Corporate reports
-
Corporate reportsWe conduct an annual stakeholder survey to improve the way we work with our stakeholders and help report on our key performance indicators.
The report includes data and feedback from the general public (consumers), people and organisations with a TGA business services account (opt-in stakeholders), and state and territory government representatives. -
Corporate reportsThe Australian Sunscreen Exposure Model performs sunscreen exposure calculations that reflect the unique conditions and practices in Australia.
-
Corporate reportsRead our business plan 2025-26 to find out about our strategic priorities and activities.
-
Corporate reportsDocuments released under the FOI Act in the 2024/25 financial year
-
Corporate reportsThis updated safety review uses the Australian Sunscreen Exposure Model to assess the risk of benzophenone as a degradant in sunscreens.
-
Corporate reportsBased on the data considered in this safety review, we recommend regulatory controls for homosalate and oxybenzone to restrict their permitted concentrations and use in therapeutic sunscreens.
-
Corporate reportsThis Cost Recovery Implementation Statement (CRIS) 2025-2026 provides information on how we implement, and cost recover our regulatory activities.
-
Corporate reportsThe report cards show the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.
-
Corporate reportsFind out about the seasonal influenza vaccines available for the 2025 southern hemisphere season.
-
Corporate reportsClarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).